Although CCL2 has strong proinflammatory effects, the activation of CCL2 pathway in CCR2-expressing macrophages and regulatory T cells exerts potent immunosuppressive effects in the tumor microenvironment, and hence, targeting the CLL2/CCR2 axis as a cancer immunotherapy method is underinvestigation [34]. The gene discussed is CCL2; the disease is cancer.